SEC Form 4 · accession 0000899243-15-008442

Wave Life Sciences, Inc. · WVE

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owners

10% Owner

Director · 10% Owner

Period of report

Aug 14, 2015

Accepted (ET)

Nov 18, 2015 · 7:29 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001631574

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Ordinary Shares^F1,F2	Nov 16, 2015	C	161,663	—	A	3,152,440	I	See Footnote
Ordinary Shares^F2	Nov 16, 2015	P	76,250	$16.00	A	3,228,690	I	See Footnote

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Series B Preferred Shares^F3,F2,F1	—	Aug 14, 2015	P	161,663	A	—	—	Ordinary Shares	161,663	161,663	I
Series B Preferred Shares^F1,F2	—	Nov 16, 2015	C	161,663	D	—	—	Ordinary Shares	161,663	0	I

F1The Series B Preferred Shares converted into Ordinary Shares on a one-for-one basis upon the closing of the Issuer's initial public offering of its Ordinary Shares and had no expiration date.
F2Shares held by Kagoshima Shinsangyo Sousei Investment Limited Partnership ("KSS"). Masaharu Tanaka, a director of the Issuer, is the representative director of Kagoshima Development Co., Ltd., the general partner of KSS and may be deemed to beneficially own the reported securities. Pursuant to Rule 16a-1 under the Securities Exchange Act of 1934, as amended (the "Act"), Mr. Tanaka disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. The filing of this Form 4 shall not be construed as an admission that Mr. Tanaka is or was for the purposes of Section 16(a) of the Act, or otherwise, the beneficial owner of any of the reported securities.
F3Share amounts reflect a 4.0415917-for-1 forward split of the Issuer's shares on November 1, 2015. The securities were purchased for $12.37 per share on a post-split basis.